| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3992893 | Journal of Thoracic Oncology | 2006 | 6 Pages |
Abstract
The chemotherapy combination of gemcitabine and carboplatin with the oral proapoptotic agent exisulind is generally well tolerated with principally hematologic toxicity. The statistical endpoint of 17 patients alive at 18 months was met, but given ongoing developments in advanced NSCLC, ECOG will not be pursuing additional trials of exisulind in NSCLC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Gregory A. MD, Sigui MS, Afshin MD, Stefan MD, Corey MD, Joan MD, David MD,